ORCHARD：奥希替尼后进展的 Biomarker-Directed 平台与 Dato-DXd 组合

类型: 论文 发表日期: 2026-03-02 入库日期: 2026-05-21 来源: PubMed 标签: EGFR L858R, 奥希替尼耐药, ORCHARD, Datopotamab deruxtecan, ADC, 临床试验

Citation

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD. PubMed: 41780641

Why this is in CCL

This is a recent ORCHARD platform-study signal around post-osimertinib treatment. It matters because EGFR-mutated NSCLC after osimertinib is increasingly treated by resistance mechanism or antibody-drug conjugate trials rather than one universal pathway.

Key takeaways

• ORCHARD is organized around post-osimertinib progression and biomarker-directed treatment.
• Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate, relevant to later-line options and clinical trial monitoring.
• This is emerging evidence; it should be tracked but not treated as a settled standard without regulatory/local availability review.

Practical relevance

• Add “ADC trials / TROP2 ADC / Dato-DXd availability” to the watchlist.
• Useful for daily agent monitoring because ADC evidence is moving quickly.